Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis

Chemotherapy

Volumn 60, Issue 5-6, 2015, Pages 325-333

  Abdel Rahman, Omar ^a   Elhalawani, Hesham ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Proteinuria; Ramucirumab; Renal impairment

Indexed keywords

RAMUCIRUMAB;

BREAST METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FOLLOW UP; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LUNG CANCER; META ANALYSIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW;

EID: 84940658390     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000437253     Document Type: Review

References (41)

1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z: Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97: 393-399.
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z: Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003; 278: 43496-43507.
3. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014; 2: 123.
4. Wilke H, Muro K, Van Cutsem EV, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235.
5. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2014; 383: 31-39.
6. Abdel-Rahman, O: Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol 2015; 93: 18-27.
7. Bozza C, Fontanella C, Buoro V, Mansutti M, Aprile G: Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? Exp Rev Clin Pharmacol 2015; 8: 251-265.
8. Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F: Ramucirumab: preclinical research and clinical development. Onco Targets Ther 2014; 7: 1997.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
10. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
12. Yardley DA, Richards PD, Reeves JA, et al: Final results of a phase 2 study of ramucirumab (RAM) plus erbulin (E) versus E in advanced metastatic breast cancer (MBC). Abstract 1035. J Clin Oncol 2014; 32(suppl):S5.
13. Yoon HH, Bendell JC, Braiteh FS, et al: Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. Abstract 4004. J Clin Oncol 2014; 32(suppl):S5.
14. Doebele RC, Spigel D, Tehfe M, et al: Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015; 121: 883-892.
15. https://clinicaltrials. gov/ct2/show/results/ NCT01160744?term=ramucirumab&rank= 38§=X01256#all (accessed March 31, 2015).
16. Zhu AX, Ryoo BY, Yen CJ, et al: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomized phase III REACH trial. Ann Oncol 2014; 25(suppl 5):v1-v41.
17. Garon EB, Ciuleanu TE, Arrieta O, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-673.
18. Hussain M, Rathkopf DE, Liu G, et al: A phase II randomized study of cixutumumab (IMCA12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (patients) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy (abstract). J Clin Oncol 2012; 30(suppl 5):97.
19. Mackey JR, Ramos-Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33: 141-148.
20. Tabernero J, Cohn AL, Obermannova R, et al: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (patients) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015; 16: 499-508.
21. Chung AS, Lee J, Ferrara N: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514.
22. Abdel-Rahman O: Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. Crit Rev Oncol Hematol 2015; 94: 45-54.
23. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
24. Abdel-Rahman O: Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumor Biol 2014; 35: 10615-10625.
25. http://emedicine. medscape. com/article/ 238158-overview (accessed April 24, 2015).
26. Peng L, Zhao Q, Ye X, Zhou Y, Hu D, Zheng S: Incidence and risk of proteinuria with aflibercept in cancer patients: A meta-analysis. PLoS One 2014; 9:e111839.
27. Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21: 1381-1389.
28. Baek S, Kim H, Lee J, et al: Renal adverse effects of sunitinib and its clinical significance: A single-center experience in Korea. Korean J Intern Med 2014; 29: 40-48.
29. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, et al: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
30. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, et al: VEGF signalling inhibitioninduced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448.
31. Larmour KE, Maxwell AP, Courtney AE: Improving early detection of chronic kidney disease. Practitioner 2015; 259: 19-23.
32. Lewis G, Maxwell AP: Timely diagnosis and treatment essential in glomerulonephritis. Practitioner 2015; 259: 13-17.
33. Warady BA, Abraham AG, Schwartz GJ, Wong CS, Muñoz A, Betoko A, Furth S: Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis 2015; 65: 878-888.
34. Bakris GL: Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008; 3(suppl 1):S3-S10.
35. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
36. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA: Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350-2360.
37. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, et al: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 2014; 64: 1282-1289.
38. Kidney Disease Outcomes Quality Initiative: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(suppl 1):S1-290.
39. Dincer M, Altundag K: Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006; 40: 2278-2279.
40. Abdel-Rahman O, Alorabi M: Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumabrelated cardiac dysfunction: preclinical and clinical considerations. Expert Rev Anticancer Ther 2015; 15: 829-837.
41. http://pi. lilly. com/us/cyramza-pi. pdf (accessed April 1, 2015).